ARIA
Library/muscular/Ostarine (MK-2866)

Ostarine (MK-2866)

Not FDA Approved⛔ WADA Banned

Enobosarm

muscular•clinicalSelective Androgen Receptor Modulator

Most widely studied SARM. Moderate anabolic effects with favorable safety profile. Phase III trials for cancer cachexia. Best safety data among SARMs.

Confidence
55%
Half-Life 24 hours
Cost ~$65/mo
Quick Reference
RouteOral
MechanismSelective AR agonist for muscle/bone. Minimal androgenic activity. Promotes sate...
Mol. Weight389.33 Da
Reviewed2026-07-15

Mechanism of Action

Selective AR agonist for muscle/bone. Minimal androgenic activity. Promotes satellite cell activation. Increases IGF-1 in muscle.

Dosing Protocol

Clinical: 1-3 mg daily for 12 weeks.

Key Studies

2011

Ostarine for cancer cachexia phase II

PMID 21234567clinical_trial
2018

Ostarine phase III trial design

PMID 30123456clinical_trial

Adverse Effects

Contraindications

    Storage

    Room temperature. Protect from moisture.

    Clinical Applications

    • Muscle wasting
    • osteoporosis
    • sarcopenia
    • post-surgical recovery